​

 

Cynaptec Pharmaceuticals, Inc. is a wholly owned American subsidiary of Lobe Sciences with offices in Stuart, Florida. Lobe Sciences has been awarded two US patents for their unique new chemical entity called Conjugated Psilocin (CP). This was developed by the company in 2023. Several additional patents for CP are awaiting review at the United States Patent and Trademark Office. When you ingest CP, it enters the body as psilocin, the active metabolite of psilocybin. Trials show that CP is highly absorbed in under an hour, and doesn't demonstrate any notable adverse effects making it the ideal drug candidate for a number of clinically relevant indicators.

 

As a result, we have selected to investigate the treatment of patients with Chronic Cluster Headache (CCH). At present, we have completed several studies and are continuing our own clinical program to treat this unbearable and unimaginably painful disease. Patients with CCH currently have no alternative medicine approved by the United States Food and Drug Administration. Once approved, we believe our drug candidate of CP, will also be granted the Orphan Drug Designation (ODD).